ptis Therapeutics (COEP) - 2023 Q1 - Quarterly Report

For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from _____________ to _____________ Table of Contents x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 COEPW Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 COEPTIS THERAPEUTICS HOLDINGS, INC. Delaware 98-1465952 (State or other jurisdiction of incorporation or org ...